Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Coherus Oncology Inc's Business Segments
Coherus Oncology Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Toripalimab
Total Revenue
$ 14
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Toripalimab0%
- Product and Service Other8.4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Toripalimab | $ 25 | - |
| Product and Service Other | $ 1 | 8.4% |
Revenue by Product & Service Category - FY
- Toripalimab95.9%
- Product and Service Other4.1%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Toripalimab | $ 12 | 95.9% |
| Product and Service Other | $ 1 | 4.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Toripalimab0%
- Product and Service Other8.4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Toripalimab | $ 25 | - |
| Product and Service Other | $ 1 | 8.4% |
Description of Coherus Oncology Inc
Coherus Biosciences Inc is a biotechnology company that is focused on the development and commercialization of biosimilar drugs.
Founded in 2010 and headquartered in Redwood City, California, Coherus is dedicated to increasing patient access to high-quality, affordable biologic medicines.
The company has a strong clinical and regulatory team with extensive experience in developing biosimilars and managing complex global development programs.
The company's leading product, UDENYCA® (pegfilgrastim-cbqv), is a biosimilar to Neulasta® and is used to reduce the risk of infection in patients undergoing chemotherapy.
UDENYCA® was approved by the U.
S.
Food and Drug Administration (FDA) in November 2018 and has been launched in the United States through a collaboration with partner, Pfizer.
Coherus has also developed its own proprietary product, CHS-1420, a biosimilar to adalimumab (Humira®).
CHS-1420 has completed its Phase 3 clinical trial and is currently awaiting FDA approval.
Coherus has a robust pipeline of other biosimilar candidates targeting leading biologic drugs, such as bevacizumab (Avastin®), ranibizumab (Lucentis®), and aflibercept (Eylea®).
Coherus is also exploring the development of novel therapies in the areas of immuno-oncology and oncology supportive care.
In addition to its biosimilar development program, Coherus has established a strong intellectual property portfolio and has entered into several key collaborations to optimize the development and commercialization of its products.
The company is focused on maintaining a strong financial position and has raised over $1 billion in funding since its inception.
Overall, Coherus Biosciences Inc is a leading biosimilar company with a strong focus on delivering high-quality, affordable medicines for patients in need.
Founded in 2010 and headquartered in Redwood City, California, Coherus is dedicated to increasing patient access to high-quality, affordable biologic medicines.
The company has a strong clinical and regulatory team with extensive experience in developing biosimilars and managing complex global development programs.
The company's leading product, UDENYCA® (pegfilgrastim-cbqv), is a biosimilar to Neulasta® and is used to reduce the risk of infection in patients undergoing chemotherapy.
UDENYCA® was approved by the U.
S.
Food and Drug Administration (FDA) in November 2018 and has been launched in the United States through a collaboration with partner, Pfizer.
Coherus has also developed its own proprietary product, CHS-1420, a biosimilar to adalimumab (Humira®).
CHS-1420 has completed its Phase 3 clinical trial and is currently awaiting FDA approval.
Coherus has a robust pipeline of other biosimilar candidates targeting leading biologic drugs, such as bevacizumab (Avastin®), ranibizumab (Lucentis®), and aflibercept (Eylea®).
Coherus is also exploring the development of novel therapies in the areas of immuno-oncology and oncology supportive care.
In addition to its biosimilar development program, Coherus has established a strong intellectual property portfolio and has entered into several key collaborations to optimize the development and commercialization of its products.
The company is focused on maintaining a strong financial position and has raised over $1 billion in funding since its inception.
Overall, Coherus Biosciences Inc is a leading biosimilar company with a strong focus on delivering high-quality, affordable medicines for patients in need.
Coherus Biosciences Inc. is a prominent player in the biotechnology sector, specializing in the development of high-quality biosimilars and biologic drugs. The company emphasizes delivering effective and cost-efficient therapeutic alternatives to expensive branded biologic medications. Coherus diverse offerings can be classified into key segments, each contributing significantly to their mission of addressing various healthcare needs.
Segments of Coherus Biosciences Inc.
1. Biosimilar Products
Coherus Biosciences is dedicated to the development and manufacturing of biosimilar products that replicate the structure, efficacy, and safety profile of established biologic drugs. This segment focuses on offering affordable alternatives to high-cost therapies, making essential treatments more accessible to patients.
Notable biosimilar products include:
- UDENYCA (pegfilgrastim): This biosimilar is designed for use in cancer patients undergoing chemotherapy to help reduce the incidence of infections by stimulating the growth of white blood cells. It provides a cost-effective option for healthcare providers.
- HarsLanza (insulin glargine): A biosimilar for Lantus, this product is aimed at managing blood glucose levels in patients with diabetes, providing an affordable alternative to the branded insulin therapy.
- CHS-1420 (adalimumab): This biosimilar mimics Humira, indicated for the treatment of various autoimmune conditions, including rheumatoid arthritis and psoriasis. It offers a more accessible treatment option for patients suffering from chronic inflammatory diseases.
2. Research and Development Services
Coherus Biosciences actively engages in providing R&D services not only for its own biosimilar products but also for other biopharmaceutical companies. This division offers comprehensive support throughout the biosimilar development lifecycle, which includes:
- Analytical testing to establish similarity to reference products.
- Clinical trial design and execution, ensuring compliance with regulatory standards.
- Process development that focuses on efficient bioprocessing and formulation.
- Regulatory support to navigate the complexities of biosimilar approval pathways.
3. Commercialization Services
Coherus provides strategic commercialization support services aimed at ensuring the successful launch and market entry of biosimilar products. This includes:
- Consulting on pricing strategies that maintain competitiveness while maximizing market access.
- Developing go-to-market strategies, ensuring that biosimilars are effectively communicated and marketed to healthcare providers and patients.
- Establishing reimbursement policies to facilitate access to biosimilars, thereby addressing potential barriers to therapy adoption.
4. Biologic Drugs
In addition to biosimilars, Coherus Biosciences is involved in the development of proprietary biologic drugs targeting various conditions. This segment encompasses innovative therapeutic monoclonal antibodies and other biologics designed to tackle challenging diseases.
Key biologic drugs include:
- CHS-2020: A monoclonal antibody designed to target urothelial cancer, representing an advancement in cancer therapeutics.
- CHS-1701: A targeted therapeutic antibody for psoriasis treatment, showcasing the company’s commitment to addressing prevalent dermatological conditions.
- CHS-131: A novel protein-based anti-cancer drug that illustrates the companys dedication to finding new treatment paradigms for cancer patients.
Conclusion
Coherus Biosciences Inc. exemplifies a forward-thinking biotechnology company with a strong commitment to enhancing patient access to life-saving therapies. By focusing on the creation of high-quality biosimilars, proprietary biologic drugs, and providing robust R&D and commercialization services, Coherus plays a critical role in the biopharmaceutical industry. The companys efforts not only help reduce healthcare costs but also improve treatment outcomes for patients suffering from various serious diseases, including cancer and autoimmune disorders. Through its innovative approach, Coherus continues to contribute significantly to the evolution and accessibility of biologic therapies in the healthcare landscape.
Segments of Coherus Biosciences Inc.
1. Biosimilar Products
Coherus Biosciences is dedicated to the development and manufacturing of biosimilar products that replicate the structure, efficacy, and safety profile of established biologic drugs. This segment focuses on offering affordable alternatives to high-cost therapies, making essential treatments more accessible to patients.
Notable biosimilar products include:
- UDENYCA (pegfilgrastim): This biosimilar is designed for use in cancer patients undergoing chemotherapy to help reduce the incidence of infections by stimulating the growth of white blood cells. It provides a cost-effective option for healthcare providers.
- HarsLanza (insulin glargine): A biosimilar for Lantus, this product is aimed at managing blood glucose levels in patients with diabetes, providing an affordable alternative to the branded insulin therapy.
- CHS-1420 (adalimumab): This biosimilar mimics Humira, indicated for the treatment of various autoimmune conditions, including rheumatoid arthritis and psoriasis. It offers a more accessible treatment option for patients suffering from chronic inflammatory diseases.
2. Research and Development Services
Coherus Biosciences actively engages in providing R&D services not only for its own biosimilar products but also for other biopharmaceutical companies. This division offers comprehensive support throughout the biosimilar development lifecycle, which includes:
- Analytical testing to establish similarity to reference products.
- Clinical trial design and execution, ensuring compliance with regulatory standards.
- Process development that focuses on efficient bioprocessing and formulation.
- Regulatory support to navigate the complexities of biosimilar approval pathways.
3. Commercialization Services
Coherus provides strategic commercialization support services aimed at ensuring the successful launch and market entry of biosimilar products. This includes:
- Consulting on pricing strategies that maintain competitiveness while maximizing market access.
- Developing go-to-market strategies, ensuring that biosimilars are effectively communicated and marketed to healthcare providers and patients.
- Establishing reimbursement policies to facilitate access to biosimilars, thereby addressing potential barriers to therapy adoption.
4. Biologic Drugs
In addition to biosimilars, Coherus Biosciences is involved in the development of proprietary biologic drugs targeting various conditions. This segment encompasses innovative therapeutic monoclonal antibodies and other biologics designed to tackle challenging diseases.
Key biologic drugs include:
- CHS-2020: A monoclonal antibody designed to target urothelial cancer, representing an advancement in cancer therapeutics.
- CHS-1701: A targeted therapeutic antibody for psoriasis treatment, showcasing the company’s commitment to addressing prevalent dermatological conditions.
- CHS-131: A novel protein-based anti-cancer drug that illustrates the companys dedication to finding new treatment paradigms for cancer patients.
Conclusion
Coherus Biosciences Inc. exemplifies a forward-thinking biotechnology company with a strong commitment to enhancing patient access to life-saving therapies. By focusing on the creation of high-quality biosimilars, proprietary biologic drugs, and providing robust R&D and commercialization services, Coherus plays a critical role in the biopharmaceutical industry. The companys efforts not only help reduce healthcare costs but also improve treatment outcomes for patients suffering from various serious diseases, including cancer and autoimmune disorders. Through its innovative approach, Coherus continues to contribute significantly to the evolution and accessibility of biologic therapies in the healthcare landscape.